scholarly journals Correlation between DCE‑MRI radiomics features and Ki‑67 expression in invasive breast cancer

2018 ◽  
Author(s):  
Ma‑Wen Juan ◽  
Ji Yu ◽  
Guo‑Xin Peng ◽  
Liu‑Jun Jun ◽  
Sun‑Peng Feng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Invasive Breast Cancer ◽  
Ki 67 ◽  
Dce Mri

1899 Correlation between Ki-67 and FISH testing of HER2 IHC 1+ early invasive breast cancer

2015 ◽  
Vol 51 ◽  
pp. S299
Author(s):  
A.C. Latorre ◽  
L. Caldarola ◽  
S. Petroni ◽  
F. Giotta ◽  
V. Lorusso ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Invasive Breast Cancer ◽  
Ki 67

scholarly journals Relationship between Ribosomal Protein S6-pS240 Expression and other Prognostic Factors in Non-Special Type Invasive Breast Cancer

Breast Care ◽  
2018 ◽  
Vol 14 (3) ◽  
pp. 171-175
Author(s):  
Frederik Cuperjani ◽  
Lumturije Gashi ◽  
Fisnik Kurshumliu ◽  
Shemsedin Dreshaj ◽  
Fitim Selimi
Keyword(s):  
Breast Cancer ◽  
Ribosomal Protein ◽  
Invasive Breast Cancer ◽  
Menopausal Status ◽  
Treatment Protocol ◽  
Prognostic Index ◽  
Disease Free Survival ◽  
Ki 67 ◽  
Free Survival ◽  
Disease Free

Background: The aim of this study was to investigate the immunohistochemical expression of ribosomal protein (RP) S6-pS240 in non-special type invasive breast cancer in relation to other prognostic markers and gain new insights to facilitate more individualized treatment. Methods: The following clinical and histopathological parameters of 120 patients were determined: S6-pS240 expression, age, menopausal status, tumor size and grade, TNM stage, Nottingham Prognostic Index (NPI), lymph node stage, estrogen and progesterone receptor (ER/PR) expression, HER2/neu amplification, lymphovascular invasion, and proliferative index as measured by Ki-67. Treatment protocol and disease-free survival were evaluated accordingly. Results: Significant positive correlations were seen between S6-pS240 expression and Ki-67 values (rho = 0.530, p < 0.001), and NPI (rho = 0.370, p < 0.001) and HER2/neu amplification (rho = 0.368, p < 0.001). A negative correlation was found between S6-pS240 and ER/PR expression (rho = 0.362, p < 0.001). Patients with negative RP S6-pS240 expression had significantly longer disease-free survival (log-rank test, p = 0.005). Conclusion: Immunohistochemical analysis of RP S6-pS240 is a valuable additional prognostic marker in patients with invasive breast cancer. Routine use of S6-pS240 immunohistochemistry is recommended.

scholarly journals P177 The prognostic significance of Ki-67 expression in patients with early invasive breast cancer

The Breast ◽  
2011 ◽  
Vol 20 ◽  
pp. S37
Author(s):  
T. Utsumi ◽  
N. Kobayashi ◽  
M. Hikichi ◽  
S. Miyajima ◽  
K. Ushimado ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Invasive Breast Cancer ◽  
Prognostic Significance ◽  
Ki 67

scholarly journals Immunohistochemical Expressions of Senescence-Associated Secretory Phenotype and Its Association With Immune Microenvironments and Clinicopathological Factors in Invasive Breast Cancer

2021 ◽  
Vol 27 ◽  
Author(s):  
Min Hui Park ◽  
Jung Eun Choi ◽  
Jae-Ryong Kim ◽  
Young Kyung Bae
Keyword(s):  
Breast Cancer ◽  
Invasive Breast Cancer ◽  
Molecular Subtype ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Luminal A ◽  
Cancer Specific Survival ◽  
Ki 67 ◽  
Entire Cohort ◽  
Secretory Phenotype

This study was undertaken to investigate immunohistochemical expression of the senescence-associated secretory phenotype (SASP) in invasive breast cancer (IBC) tissues and to determine relationships between SASP positivity and tumor microenvironments and the clinicopathological characteristics of IBC. Immunohistochemistry for senescence markers, that is, high mobility group box-1 (HMGB1), p16, p15, and decoy receptor 2 (DCR2), was performed in tissue microarrays of 1140 IBC samples. Cases positive for at least one of these four markers were considered SASP-positive. Relations between SASP and tumor characteristics, including immune microenvironments (stromal tumor-infiltrating lymphocytes [sTILs] density and numbers of intraepithelial CD103-positive [iCD103 + ] lymphocytes) and clinical outcomes were retrospectively evaluated. HMGB1, p16, p15, or DCR2 was positive in 6.7%, 26.6%, 21.1%, and 26.5%, respectively, of the 1,140 cases. Six hundred and five (53.1%) cases were SASP positive, and SASP positivity was significantly associated with histologic grade 3, high-sTIL and iCD103 + lymphocyte counts, absence of ER or PR, and a high Ki-67 index. Although SASP did not predict breast cancer-specific survival (BCSS) or disease-free survival (DFS) in the entire cohort, SASP positivity in luminal A IBC was associated with poor BCSS and DFS. However, patients with SASP-positive TNBC showed better survival than those with SASP-negative TNBC. In multivariate analysis, SASP positivity was an independent prognostic factor in both luminal A IBC and TNBC, although the effect on prognosis was the opposite. In conclusion, SASP would be involved in the modulation of immune microenvironments and tumor progression in IBC, and its prognostic significance depends on molecular subtype.

scholarly journals Reproducibility of mRNA-Based Testing of ESR1, PGR, ERBB2, and MKI67 Expression in Invasive Breast Cancer—A Europe-Wide External Quality Assessment

Cancers ◽  
2021 ◽  
Vol 13 (18) ◽  
pp. 4718
Author(s):  
Ramona Erber ◽  
Arndt Hartmann ◽  
Peter Andreas Fasching ◽  
Matthias Ruebner ◽  
Robert Stöhr ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Assessment ◽  
Invasive Breast Cancer ◽  
External Quality Assessment ◽  
External Quality ◽  
Ki 67 ◽  
Erbb2 Mrna ◽  
Reproducible Method ◽  
Sensitivity Specificity

Estrogen receptor (ER), progesterone receptor (PgR), Ki-67, and HER2 immunohistochemistry (IHC) together with HER2 in situ hybridization (ISH) are utilized to classify invasive breast cancer (IBC) into predictive molecular subtypes. As IHC evaluation may be hampered by analytical errors, gene expression assays could offer a reliable alternative. In this first Europe-wide external quality assessment (EQA) study, we investigated performance of mRNA-based Xpert® Breast Cancer STRAT4 (CE-IVD) in five European laboratories. The cohort comprised ten pre-therapy IBC core biopsies diagnosed in the coordinating center (CC). STRAT4 binary (positive or negative) mRNA results of each marker (ESR1, PGR, ERBB2, MKI67) were compared with the gold standard IHC/ISH performed by the CC. Sensitivity, specificity, and accuracy of ESR1 and ERBB2 mRNA were 100% for all samples. In contrast, PGR expression was falsely negative for one case by two sites and MKI67 falsely negative for two cases (respectively by four and one sites). These cases had STRAT4 expression values close to assay cut-offs and immunohistochemically presented heterogeneous low positive PgR and heterogeneous Ki-67. Our EQA shows that STRAT4 mRNA assay may be a reproducible method to evaluate ER, PgR, HER2, and Ki-67 status. However, cases with expression values close to assay cut-offs should be carefully reviewed.

Invasive breast cancer: Ki-67 evaluation in 3909 early breast cancer patients

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 678-678
Author(s):  
A. Auriemma ◽  
A. Mercanti ◽  
E. Fiorio ◽  
M. Mandarà ◽  
M. Giovannini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Invasive Breast Cancer ◽  
Breast Cancer Patients ◽  
Ki 67

Expression of androgen receptor and epidermal growth factor receptor in invasive breast cancer: A retrospective study of 1,438 patients from China.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e12587-e12587
Author(s):  
Junqing Chen ◽  
Zhanhong Chen ◽  
Xiaojia Wang
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Retrospective Study ◽  
Androgen Receptor ◽  
Invasive Breast Cancer ◽  
Growth Factor Receptor ◽  
Ki 67 ◽  
Egfr Expression ◽  
Significant Difference ◽  
Epidermal Growth

e12587 Background: Triple-negative breast cancer (TNBC) is lack of clinically efficient targeted therapies and usually more aggressive with higher rate of distant metastasis and poor overall survival as compared with other breast cancer subtypes. Recent evidence demonstrates that androgen receptor (AR) and epidermal growth factor receptor (EGFR) are involved in the pathogenesis of TNBC. The aim of this study was to explore the expression of AR and EGFR in invasive breast cancer and evaluate the potential of AR and EGFR as biomarkers in TNBC. Methods: In this retrospective study, we analyzed 1438 patients with invasive breast cancer in our hospital from 2015 to 2016. Estrogen receptor (ER) expression, progesterone receptor (PR) expression, Ki-67 index, AR and EGFR expression were detected by immunohistochemical assay. HER2 state was determined by immunohistochemical and FISH assay. χ2 test was used for the analysis. Results: Among 1438 breast cancer patients, 272 (18.9%) cases were TNBC and 1165 (81.0%) cases were non-TNBC. TNBC patients had a low AR expression as compared with non-TNBC patients (29.8% vs 90.2%). There was a significant difference in AR expression in TNBC compared in non-TNBC ( P= 0.000). In contrast, TNBC patients had a high EGFR expression as compared with non-TNBC patients (90.9% vs 21.1%) ( P= 0.000). There was also a significant difference in Ki-67 index in TNBC compared in non-TNBC (89.9% vs 70.1%) ( P= 0.000). AR-positive TNBC patients had a low Ki-67 index expression as compared to AR-negative TNBC (82.7% vs 93.6%). No significant difference of EGFR expression was found between AR-positive TNBC and AR-negative TNBC. Conclusions: AR expression is associated with Ki-67 index and may be as a potential biomarker for targeted therapy in AR-positive TNBC patients.

Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancer

2012 ◽  
Vol 135 (3) ◽  
pp. 885-892 ◽  
Author(s):  
Katharina Heusinger ◽  
Sebastian M. Jud ◽  
Lothar Häberle ◽  
Carolin C. Hack ◽  
Peter A. Fasching ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mammographic Density ◽  
Invasive Breast Cancer ◽  
Proliferation Marker ◽  
Ki 67
Sign in / Sign up

Export Citation Format

Share Document